COVID-19 Seroprevalence Study in French Guiana
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Coronavirus Infection
- COVID-19
- SARS-CoV Infection
- Severe Acute Respiratory Syndrome
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Prevention
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Both males and females
Description
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana. This study is a interventional study that present minimal risks and co...
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana. This study is a interventional study that present minimal risks and constraints. The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.
Tracking Information
- NCT #
- NCT04490850
- Collaborators
- Institut Pasteur de la Guyane
- Laboratoire de biologie médicale, Institut Pasteur de la Guyane
- Laboratoire de biologie médicale de Kourou, French Guiana
- Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana
- Eurofins
- Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guiana
- Investigators
- Principal Investigator: Claude Flamand, PhD Institut Pasteur de la Guyane, Head of Epidemiology Unit
Get Well Soon